{
  "docId": "019de076-f846-767d-9b7f-8682a04c3e89",
  "docSlug": "d28195e1bb64bc51ad898953c5c30263",
  "documentTitle": "Boundless Bio | IPO Presentation Deck | 51 slides",
  "authorId": "boundless-bio",
  "authorName": "Boundless Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 33,
  "pageCount": 51,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The slide highlights the 60mg dose as the MTD (Maximum Tolerated Dose) and shows it crosses the threshold for tumor regression.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f846-767d-9b7f-8682a04c3e89/33",
  "deckHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89",
  "deckJsonHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89.json",
  "deckAnchorHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.48,
        "w": 0.42,
        "x": 0.53,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Fitted PK Profiles of BBI-355 at 20, 40, 60, and 80 mg PO Q2D for 2 Weeks",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a390a441-3a6f-471a-8777-c944379f7433",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.0019
      },
      "kind": "list",
      "text": "Human PK data of BBI-355 dosed PO every other day (Q2D)\n- Good oral bioavailability\n- Average Cmax and AUC dose proportional from 20 to 80 mg\n- Average T1/2: ~40h -> drug accumulation (~2 to 3-fold)\n- Modest inter-subject variability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cfa56f5-e535-4603-a4e0-1dac89ecf014",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.18,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "AUC: area under the curve; MTD: maximum tolerated dose; PO: oral; Q2D: every two days; SS: steady state",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6aa80cc2-3e84-44ed-84ee-007306dc82bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.92,
        "x": 0.04,
        "y": 0.7
      },
      "kind": "table",
      "text": "Dose/Schedule, T1/2 (hr), Free Cmax at SS (ng/mL), Free AUC0-48h at SS (h*ng/mL), Free AUC0-366h (h*ng/mL), Notes",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37aaac91-7b34-4be2-98a7-f22f89dad5d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "Human pharmacokinetic (PK) preliminary data of BBI-355 shows dose-proportionality and achieving exposures in the predicted therapeutically active range at 60 mg PO Q2D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9027dc6-33a8-40a5-a157-14ca01024a1e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "47633591-7ac1-4eba-b98d-b956c0349ef6",
      "evidence": "chart/line: Fitted PK Profiles of BBI-355 at 20, 40, 60, and 80 mg PO Q2D for 2 Weeks",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}